| Andrew Geller, MD | |
|
800 Washington St, Norwood, MA 02062 | |
| (781) 769-2950 | |
| Not Available |
| Full Name | Andrew Geller |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 800 Washington St, Norwood, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427016906 | NPI | - | NPPES |
| C07932 | Other | MA | BS |
| 710044 | Other | MA | TUFTS |
| 6190588 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 43043 (Massachusetts) | Primary |
| Entity Name | Steward Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780971275 PECOS PAC ID: 0244401404 Enrollment ID: O20110919000768 |
News Archive
Earlier this year, researchers at the University of Washington reported that they had developed a toxin-nanoparticle combination that inhibits brain cancer invasion when added to tumor cells growing in culture.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for Enhancing Immunogenicity of Antigen has been allowed for issuance. This patent will be #1,303,299 when granted, and will be licensed exclusively to Advaxis by the University of Pennsylvania.
Women account for approximately half of all individuals living with HIV worldwide, and researchers wanted to identify the risk factors that increase susceptibility of women to genital infection.
RepRegen™, the ‘smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Geller, MD 944 Washington St #1, South Easton, MA 02375-1177 Ph: (508) 238-8646 | Andrew Geller, MD 800 Washington St, Norwood, MA 02062 Ph: (781) 769-2950 |
News Archive
Earlier this year, researchers at the University of Washington reported that they had developed a toxin-nanoparticle combination that inhibits brain cancer invasion when added to tumor cells growing in culture.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for Enhancing Immunogenicity of Antigen has been allowed for issuance. This patent will be #1,303,299 when granted, and will be licensed exclusively to Advaxis by the University of Pennsylvania.
Women account for approximately half of all individuals living with HIV worldwide, and researchers wanted to identify the risk factors that increase susceptibility of women to genital infection.
RepRegen™, the ‘smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.
› Verified 2 days ago
Peter J Dimatteo, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Norwood, MA 02062 Phone: 781-769-2950 | |
Dr. Samuel Seung-ho Kim, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Norwood, MA 02062 Phone: 781-278-6260 | |
Henry Rosenkranz, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Norwood, MA 02062 Phone: 781-769-4000 | |
Michael J. Regan Iv, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Norwood, MA 02062 Phone: 781-769-4000 | |
Vincent Meoli, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Norwood, MA 02062 Phone: 781-769-2950 | |
Erin Lucille Mccann, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Norwood, MA 02062 Phone: 781-769-2950 | |
Yusef Haj-darwish, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1210 Boston Providence Tpke, Norwood, MA 02062 Phone: 781-255-0500 Fax: 781-255-0400 |